ALLERGIC REACTION UPON INTRAVITREAL ADMINISTRATION OF ANTI–VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS

    loading  Checking for direct PDF access through Ovid

Abstract

Purpose:

To describe the patient's allergic response to anti–vascular endothelial growth factor drugs after receiving intravitreal bevacizumab for choroidal neovascularization.

Methods:

Clinical case report.

Results:

Formal allergy evaluation revealed hypersensitivity to bevacizumab and ranibizumab, but not to pegaptanib or aflibercept.

Conclusion:

Bevacizumab and ranibizumab are derivatives of murine monoclonal antibodies, whereas pegaptanib is an aptamer and aflibercept is a fusion protein of human origin. These chemical origins may allow patients to receive pegaptanib or aflibercept despite having allergy to bevacizumab or ranibizumab.

Related Topics

    loading  Loading Related Articles